The challenge of diabetes now touches every country of the world and disproportionately affects people in resource-poor settings. In low- and middle-income countries, where 80% of people with diabetes live, the level of awareness of the condition remains low in spite of the growing burden. Diabetes care is hindered by limited healthcare capacity and shortage of healthcare professionals who can diagnose and effectively treat diabetes. Lack of a steady supply of diabetes medicines and equipment is also among the barriers to effective diabetes care.
As a global healthcare company, providing approximately half of the world’s insulin, Novo Nordisk has a responsibility to help close the gap in access to diabetes care. For more than fifteen years we have been working with partners to improve access to care.